Genentech, a member of the Roche Group, has announced compelling one-year data from the Phase III OCARINA II study of its investigational subcutaneous formulation of Ocrevus® (ocrelizumab). The study evaluated the efficacy and safety of a twice-yearly, 10-minute subcutaneous injection in patients with progressive and relapsing forms of multiple sclerosis (MS).
The results demonstrated that subcutaneous Ocrevus provided near-complete suppression of clinical relapses and brain lesions over a 12-month period. These findings suggest that the subcutaneous formulation may offer a more convenient and equally effective alternative to the currently approved intravenous administration of Ocrevus.
The positive outcome of the OCARINA II study reinforces Genentech’s commitment to improving the lives of people with MS by developing innovative treatment options that address the diverse needs of this patient population. The company plans to submit the subcutaneous formulation of Ocrevus for regulatory approval, potentially expanding the available treatment options for MS patients worldwide.